Non-Clinical Evaluation Expert Committee ERA Team, Drug Evaluation Committee, The Japan Pharmaceutical Manufacturers Association (JPMA), Tokyo, Japan; Drug Safety Research and Evaluation, Takeda Pharmaceutical Co., Ltd., 26-1-2, Muraoka-Higashi, Fujisawa, Kanagawa, 251-8555, Japan.
Non-Clinical Evaluation Expert Committee ERA Team, Drug Evaluation Committee, The Japan Pharmaceutical Manufacturers Association (JPMA), Tokyo, Japan; Central Pharmaceutical Research Institute, Japan Tobacco Inc., Murasakicho 1-1, Takatsuki, Osaka, 569-1125, Japan.
Regul Toxicol Pharmacol. 2018 Nov;99:98-104. doi: 10.1016/j.yrtph.2018.09.014. Epub 2018 Sep 14.
The distribution of active pharmaceutical ingredients (APIs) in prescription medicines for human consumption in Japan was estimated using the public database of the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). From the latest NDB, 2058 APIs were identified, and the prescription weight exceeded 1 tonne/year for 711 APIs. Of these, 298 APIs were selected for further analysis after removing 413 APIs that were not covered by current environmental risk assessment (ERA) directives or were combination products. Among the 298 APIs, 43 were relatively newly branded APIs that have been available on the Japanese market since 2001 or later and have no generic drugs, and only 5 of the branded APIs are used by more than 1% of the population. When prescription data from the 47 prefectures in Japan were analyzed, prescription weights for 257 of the 298 APIs were the highest in Tokyo, probably because of its large population. Though it has both advantages and limitations, this novel method based on a non-profit public database can provide a transparent, unbiased and cost-effective solution for the estimation of the environmental exposure of generic and branded human medicines distributed with prescriptions in Japan.
利用日本国民健康保险索赔和特定健康检查全国数据库(NDB)的公共数据库,估算了日本用于人类消费的处方药品中活性药物成分(API)的分布情况。从最新的 NDB 中,确定了 2058 种 API,711 种 API 的处方重量超过 1 吨/年。其中,在剔除了 413 种不受现行环境风险评估(ERA)指令涵盖或属于组合产品的 API 后,选择了 298 种 API 进行进一步分析。在这 298 种 API 中,有 43 种是相对较新的品牌 API,自 2001 年或之后在日本市场上推出,且没有仿制药,只有 5 种品牌 API 的使用人群超过 1%。当分析日本 47 个都道府县的处方数据时,298 种 API 中有 257 种在东京的处方重量最高,这可能是因为其人口众多。尽管这种基于非营利公共数据库的新方法有其优势和局限性,但它为估算在日本开处方分发的通用和品牌人用药物的环境暴露情况提供了一种透明、公正和具有成本效益的解决方案。